@article{oai:u-ryukyu.repo.nii.ac.jp:02016892,
 author = {Nagayama-Urasoe, Chiaki and Umikawa, Masato and Asato, Tsuyoshi and Nagai, Yutaka and Aoki, Yoichi and Kariya, Ken-ichi},
 issue = {1-2},
 journal = {琉球医学会誌 = Ryukyu Medical Journal},
 note = {Patient-derived xenograft (PDX) models are useful for preclinical evaluation of anticancer agents. However, establishing PDX models of cervical cancers are known to be challenging. We modified a protocol from the existing literature and established a model of an HPV16-positive squamous cell carcinoma on scid mice. The xenograft was positive for p16INK4a even after a passage, indicating the continued involvement of the E7 viral oncoprotein in abnormal cell growth. After 24 days of treatment with a nucleoside analog, gemcitabine, tumor growth was found to be suppressed in a dose-dependent manner, and the tumor became undetectable after high-dose treatment. Cediranib, an orally bioavailable inhibitor of neovascularization, reversed tumor growth until it was barely detectable. A hydrophobic cancer stem cell inhibitor, salinomycin, did not show any significant effect when used alone, but showed a tendency to act synergistically with low-dose gemcitabine. Although further procedural refinements are required, the model appeared to be useful for preclinical evaluation of various anticancer agents, including novel ones that target specific molecules., 論文},
 pages = {25--28},
 title = {Evaluation of candidate therapies using a patient-derived cervical cancer xenograft model},
 volume = {36}
}